- Home
- GAUZ vs PBYI Comparison
GAUZ vs PBYI Comparison
Compare GAUZ & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAUZ
- PBYI
- Stock Information
- Founded
- GAUZ 2009
- PBYI 2010
- Country
- GAUZ Israel
- PBYI United States
- Employees
- GAUZ N/A
- PBYI N/A
- Industry
- GAUZ Industrial Machinery/Components
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GAUZ Miscellaneous
- PBYI Health Care
- Exchange
- GAUZ Nasdaq
- PBYI Nasdaq
- Market Cap
- GAUZ 133.9M
- PBYI 126.5M
- IPO Year
- GAUZ 2024
- PBYI N/A
- Fundamental
- Price
- GAUZ $8.03
- PBYI $2.90
- Analyst Decision
- GAUZ Strong Buy
- PBYI Strong Buy
- Analyst Count
- GAUZ 4
- PBYI 1
- Target Price
- GAUZ $16.25
- PBYI $7.00
- AVG Volume (30 Days)
- GAUZ 55.5K
- PBYI 566.4K
- Earning Date
- GAUZ 11-12-2024
- PBYI 11-07-2024
- Dividend Yield
- GAUZ N/A
- PBYI N/A
- EPS Growth
- GAUZ N/A
- PBYI 492.79
- EPS
- GAUZ N/A
- PBYI 0.47
- Revenue
- GAUZ $94,346,000.00
- PBYI $243,569,000.00
- Revenue This Year
- GAUZ $41.29
- PBYI N/A
- Revenue Next Year
- GAUZ $36.94
- PBYI N/A
- P/E Ratio
- GAUZ N/A
- PBYI $6.24
- Revenue Growth
- GAUZ 29.76
- PBYI 6.30
- 52 Week Low
- GAUZ $6.78
- PBYI $2.23
- 52 Week High
- GAUZ $17.10
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- GAUZ N/A
- PBYI 51.31
- Support Level
- GAUZ N/A
- PBYI $2.32
- Resistance Level
- GAUZ N/A
- PBYI $3.25
- Average True Range (ATR)
- GAUZ 0.00
- PBYI 0.32
- MACD
- GAUZ 0.00
- PBYI -0.03
- Stochastic Oscillator
- GAUZ 0.00
- PBYI 48.74
About GAUZ Gauzy Ltd. Ordinary Shares
Gauzy Ltd is a integrated light and vision control company, Its products include suspended particle device, or SPD, and liquid crystal, or LC, films for smart glass applications, as well as camera monitoring systems, or CMS, and other advanced driver assistance systems, or ADAS, solutions. It has three operating segments. Architecture and automotive segment focuses on sales that enable OEMs to incorporate the Company's technology in glass rooftops, side windows and windshields. Safety tech segment focuses on sales of advanced driver assistance systems for buses, coaches, recreational vehicles and specific vehicles. Aeronautics segment focuses on the sale of shading and cabin management systems in private and commercial aircraft and helicopters. Key revenue is generated from Aeronauctis.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.